COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2020 and September 30, 2019 is as follows (in thousands):

Nine Months Ended September 30, 2020	Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)			Contingent Consideration  Liability Related to Acquisition of Derma Sciences		Location in Financial Statements
	Long-term			Long-term
Balance as of January 1, 2020	$	14,210		$	230
Loss from change in fair value of contingent consideration liabilities	(45		)	—		Research and development
Balance as of September 30, 2020	$	14,165		$	230

Nine Months Ended September 30, 2019	Contingent Consideration Liability Related to Acquisition of Arkis (See Note 3)		Contingent Consideration  Liability Related to Acquisition of Derma Sciences		Location in Financial Statements
	Long-term		Long-term
Balance as of January 1, 2019	$	—	$	230
Additions from acquisition of Arkis	13,100		—
Balance as of September 30, 2019	$	13,100	$	230